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In type 1 diabetes, an autoimmune event increases oxidative
stress in islet  cells, giving rise to cellular dysfunction and
apoptosis. Lipoxygenases are enzymes that catalyze the oxygen-
ation of polyunsaturated fatty acids that can form lipid metabo-
lites involved in several biological functions, including oxidative
stress. 12-Lipoxygenase and 12/15-lipoxygenase are related but
distinct enzymes that are expressed inpancreatic islets, but their
relative contributions to oxidative stress in these regions are still
being elucidated. In this study, we usedmice with global genetic
deletion of the genes encoding 12-lipoxygenase (arachidonate
12-lipoxygenase, 12S type [Alox12]) or 12/15-lipoxygenase
(Alox15) to compare the influence of each gene deletion on 
cell function and survival in response to the cell toxin strepto-
zotocin. Alox12/ mice exhibited greater impairment in glu-
cose tolerance following streptozotocin exposure than WT
mice, whereasAlox15/mice were protected against dysglyce-
mia. These changes were accompanied by evidence of islet oxi-
dative stress in Alox12/mice and reduced oxidative stress in
Alox15/mice, consistent with alterations in the expression of
the antioxidant response enzymes in islets from these mice.
Additionally, islets from Alox12/ mice displayed a compen-
satory increase in Alox15 gene expression, and treatment of
these mice with the 12/15-lipoxygenase inhibitor ML-351 res-
cued the dysglycemic phenotype. Collectively, these results
indicate that Alox12 loss activates a compensatory increase in
Alox15 that sensitizes mouse  cells to oxidative stress.
Type 1 diabetes (T1D)3 is a debilitating chronic disease
caused by autoimmunity-mediated destruction of insulin-pro-
ducing  cells in pancreatic islets. Because of the loss of these
cells, individuals who have T1Dmust rely on exogenous insulin
to maintain glucose homeostasis (1). A complex interplay
between genetic and environmental factors leads to the auto-
immune attack of the  cells, and recent studies suggest that 
cell dysfunction may contribute to neoantigen formation,
which instigates autoimmunity (2–4). Oxidative stress result-
ing from an imbalance in favor of oxidants over antioxidants
has been suggested as a primary cause of  cell dysfunction in
T1D (5–7). Because of their role in the production and release
of insulin,  cells generate endogenous reactive species such as
hydrogen peroxide, hydroxyl radicals, and peroxynitrites. Para-
doxically,  cells possess relatively low antioxidative capacity
because of low expression of antioxidant enzymes (8, 9). Inter-
ventions that augment antioxidant capacity inmousemodels of
T1D protect against immunity-mediated cell destruction (10,
11). Hence, uncovering mechanisms that influence the oxida-
tive stress response in  cells would provide new targets for the
treatment of this disease.
Lipoxygenases (LOXs) are lipid-processing enzymes that
catalyze the oxygenation of polyunsaturated fatty acids (12).
Depending on the specific substrate, lipoxygenases produce a
variety of different lipid metabolites that regulate a host of bio-
logical functions and disease states (13–15). In mice, the gene
Alox15 encodes for “leukocyte-type” 12-lipoxygenase (known
as 12/15-LOX), which catalyzes oxygenation of lipids at carbon
12 or 15 (16, 17). The related gene Alox12 encodes “platelet-
type” 12-lipoxygenase (known as 12-LOX), which oxygenates
lipids at carbon 12. Both enzymes catalyze the oxygenation of
the polyunsaturated fatty acid arachidonic acid, with 12/15-
LOX forming 12- and 15-hydroxyeicosatetraenoic acid (HETE)
in a 6:1 ratio, whereas 12-LOX forms only 12-HETE. The activ-
ity of 12/15-LOX and itsmajor lipidmetabolite, 12-HETE, have
been linked to the pathogenesis of T1D.Mice harboring whole-
body knockout ofAlox15 showprotection from low-dose strep-
tozotocin (STZ)–induced diabetes (18). Likewise, non-obese
diabetic mice with whole-body knockout of Alox15 also show
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protection from the development of T1D (19). This protective
effect of loss ofAlox15 is likely due to pancreas expression of the
enzyme, asmice with a pancreas-specific deletion ofAlox15 are
also protected from low-dose STZ–induced diabetes (18). The
specific mechanism underlying this protection has not been
identified, but studies have highlighted loss of the lipid meta-
bolite 12-HETE as one possible mechanism. This possibility is
supported by evidence that islet exposure to 12-HETE alone
can reduce glucose-stimulated insulin secretion and increase
islet death (20, 21). In contrast, a role for 12-LOX, which also
produces 12-HETE and related eicosanoids, has never been
studied in the context of diabetes pathogenesis in the mouse,
although it seems to be the primary enzyme in human islets.We
reasoned that because both 12-LOX and 12/15-LOX can make
12-HETEandrelatedeicosanoids, lossofAlox12 should showsim-
ilar protection as loss ofAlox15. In this study,we sought todirectly
compare the effect of loss ofAlox12 versus Alox15 in the setting of
T1D.
Results
Deletion of Alox12 exacerbates STZ-induced diabetes,
whereas deletion of Alox15 is protective
We sought to assess the metabolic effects of whole-body
deletion of the genes encoding 12/15-LOX and 12-LOX
(Alox15 and Alox12, respectively) in mice on the C57BL6/J
background. As shown in Fig. S1,A–D,Alox15/,Alox12/,
and their WT control littermate mice at 8 weeks of age exhib-
ited no differences in body weight, glucose tolerance (by intra-
peritoneal glucose tolerance tests (GTTs)), or  cell mass (by
histomorphometric analysis of immunostained pancreata).
These results are consistent with prior findings (22–24) that
loss of Alox12 or Alox15 does not appear to affect the normal
development of  cells or whole-body glucose homeostasis.
To assess whether loss of Alox15 and Alox12 negatively or
positively affects  cell function during the development of dia-
betes, we leveraged the multiple low-dose STZ model (55
mg/kg body weight STZ intraperitoneally daily for 5 days) to
induce diabetes. In this  cell toxicity model, mice develop a
T1D-like phenotype with local islet inflammation and conse-
quent hyperglycemia over 4 weeks (24–26). As expected, WT
mice developed overt diabetes (blood glucose  300 mg/dl)
within 14 days following STZ injections (Fig. 1A, closed circles).
Consistent with data published previously (19), Alox15/
mice were protected from overt diabetes following STZ (Fig.
1A, gray circles). In striking contrast,Alox12/mice exhibited
more severe hyperglycemia thanWTmice by 14 days following
STZ and continuing through the conclusion of the study at 28
days (Fig. 1A, open circles). GTTs performed 4 days following
STZ revealed that Alox12/ mice were significantly more
glucose-intolerant than WT and Alox15/ mice, whereas
Alox15/mice showed protection from STZ-induced glucose
intolerance compared with WT mice (Fig. 1, B and C).
Wenextevaluatedcellmass inSTZ-treatedmice.As shownin
Fig. 1, D and E, STZ-treated Alox12/ mice exhibited a signifi-
cant 1.8-fold reduction in cell mass comparedwith STZ-treated
WTmice. In contrast,  cell mass was more than 2-fold higher in
STZ-treated Alox15/ mice compared with STZ-treated WT
mice (Fig. 1, D and E). Together, these data suggest that loss of
Alox12 exacerbates inflammation-induced  cell dysfunction,
whereas loss ofAlox15 is protective in this setting.
Deletion of Alox12 exacerbates inflammation-induced
oxidative stress in cells
12-HETE, a lipid product of 12-LOX and 12/15-LOX, is
linked to oxidative stress in islets (27). We therefore asked
whether oxidative stress in  cells differed in WT, Alox15/,
Figure 1.DeletionofAlox12 exacerbateswhereas deletionofAlox15protects against STZ-induceddiabetes.A, random feedbloodglucose levels ofWT
and Alox12/ and Alox15/mice following the STZ regime. B, analysis of glucose tolerance (GTT) inWT, Alox12/, and Alox15/mice 4 days following the
STZ regime. C, area under the curve analysis of GTT post STZ. D, representative images of insulin immunohistochemistry staining of pancreata for WT,
Alox12/, and Alox15/ used for determination of  cell mass. E, analysis of  cell mass in WT, Alox12/, and Alox15/ mice following STZ. n  3
mice/experimental group for all experiments. *, p 0.05 compared with the WT; #, p 0.05 compared with Alox15/mice.
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andAlox12/mice after STZ treatment.We examined oxida-
tive stress in tissue sections from STZ-treated control and
knockout mice by analysis of islet 4-hydroxynoneal (4-HNE)
(28, 29) by immunofluorescence. STZ-treated Alox15/mice
exhibited 2-fold reduced 4-HNE immunostaining intensity
compared with STZ-treated WT mice (Fig. 2, A and B). How-
ever, in agreement with their exacerbated diabetic phenotype,
Alox12/ mice exhibited a significant 1.4-fold increase in
4-HNE immunostaining intensity compared with STZ-treated
WTmice (Fig. 2,A and B). To determine whether the opposing
effects on oxidative stress observed between Alox15/ and
Alox12/mice could be due to differential production of anti-
oxidant enzymes, we co-immunostained pancreatic sections
from STZ-treated WT, Alox15/, and Alox12/ mice for
insulin and the antioxidant enzymes GSH peroxidase 1 (GPX1)
and catalase (CAT). We observed significant increases in  cell
immunostaining intensities of both GPX1 and CAT in
Alox15/mice comparedwith bothWTandAlox12/mice)
(Fig. 2,C–F). Conversely,Alox12/mice showed a significant
decrease in  cell GPX1 immunostaining compared with WT
andAlox15/mice (Fig. 2,C andD). These results suggest that
loss of Alox15 and Alox12 result in changes in antioxidant pro-
tein levels in cells thatmay explain their observed effects on
cell oxidative stress.
Figure 2. Deletion of Alox12 exacerbates inflammation-induced oxidative stress in  cells. A, representative images of staining for insulin (green), the
oxidative stressmarker 4-HNE (pink), andnuclei (blue) inWT,Alox12/, andAlox15/mice following STZ-induceddiabetes.DAPI, 4,6-diamidino-2-phenylin-
dole. B, quantification of 4-HNEmean intensity inWT, Alox12/, and Alox15/mice following STZ-induced diabetes. C, representative images of staining for
insulin (green), the oxidative stress marker GPX-1 (red), and nuclei (blue) in WT, Alox12/, and Alox15/mice following STZ-induced diabetes. D, quantifica-
tion of GPX-1mean intensity inWT,Alox12/, andAlox15/mice following STZ-induceddiabetes. E, representative images of staining for insulin (green), the
oxidative stress marker CAT (red), and nuclei (blue) in WT, Alox12/, and Alox15/ mice following STZ-induced diabetes. F, quantification of CAT mean
intensity in WT, Alox12/, and Alox15/mice following STZ induced diabetes. n 3mice/experimental group for all experiments. *, p 0.05; A.U, arbitrary
units.
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Alox12 deletion exacerbates reactive oxygen species
accumulation in cells
To determine whether the increased oxidative stress was a
result of elevated reactive oxygen species (ROS) generation in
the islet, we employed the redox biosensor redox-sensitive GFP
(roGFP) (30, 31) to measure ROS accumulation dynamically.
Islets were transduced with an adenovirus harboring roGFP
and then treated for 16 hwith a proinflammatory cytokinemix-
ture (IL1-, TNF, and IFN-) to approximate inflammation-
induced oxidative stress. As shown in the representative ratio-
metric image in Fig. 3A and as quantified in Fig. 3B, islets from
WT mice exhibited an increased redox ratio after cytokine
treatment, signifying that cytokines increased ROS. In support
of our observations in vivo, cytokine-treated Alox15/ islets
exhibited significantly less ROS elevation in response to cyto-
kines compared with WT islets. In contrast, cytokines elicited
significantly increased ROS in Alox12/ islets compared with
WT islets (Fig. 3, A and B). Collectively, these results suggest
that deletion of Alox15 protects against ROS accumulation,
whereas deletion of Alox12 promotes enhanced oxidative
stress.
Alox12 deletion decreases circulating eicosanoid levels inmice
The products of LOXs are biologically active lipid metabo-
lites, and loss of LOXs is expected to alter the levels or ratios of
these metabolites, which may account for the effects observed
in our mice. To determine the changes in eicosanoid profiles of
Alox12/ and Alox15/ mice, we performed LC-MS/MS
analysis of key eicosanoids in the circulation ofmice. There was
no statistically significant difference in circulating levels of
5-HETE, 15-HETE, 13-HODE, 17-HDHA, and LTB4 in
Alox12/ and Alox15/ mice compared with WT mice
(Table 1). Levels of 12-HEPE were significantly increased in
Alox15/mice compared with controls. There were expected
reductions in 12-HETE, which reached statistical significance
in Alox12/ mice (p  0.02) and approached significance in
Alox15/mice (p 0.06) compared withWT controls. These
data confirm that our knockout mice exhibited reductions
in the major 12-LOX and 12/15-LOX metabolite in the
circulation.
Alox12 deletion increases STZ-induced oxidative damage
through reciprocal up-regulation of Alox15
We next asked how loss of Alox12 could render mice more
sensitive to STZ-induced diabetes. Because Alox15 and Alox12
are functionally related, we analyzed the expression of each
gene in both Alox15/ and Alox12/ islets and compared
them with expression levels in WT controls. Quantitative PCR
analysis of Alox12 mRNA in WT, Alox15/, and Alox12/
islets show the expected decrease in Alox12/ islets and no
significant change in Alox15/ islets (Fig. 4A). Strikingly,
Alox12/mice exhibited a 28-fold increase in Alox15mRNA
expression compared with the WT (Fig. 4B), suggesting that
loss ofAlox12 leads to a compensatory up-regulation ofAlox15
but not vice versa.Wehypothesized that the striking reductions
in 12-HETE observed inAlox12/mice (Table 1) might cause
a compensatory increase inAlox15 in this setting, implying that
12-HETE levels might inversely regulate Alox15. To test this
hypothesis, we incubated Min6  cells overnight with 100 nM
12-HETE and performed gene expression analysis by quantita-
tive PCR. Treatment with 12-HETE caused a significant reduc-
tion in Alox15 expression compared with the control (Fig. 4C),
a result that supports our hypothesis. We also sought to deter-
mine the effect of 12-HETE on the expression of antioxidant
genes. Incubation of Min6 cells with 12-HETE caused a signif-
icant decrease in Gpx1 expression (Fig. 4D). The expression of
Catalase was increased following 12-HETE incubation but was
not statistically significant (Fig. 4E).
To determine whether the increase in Alox15 expression
contributes to the increased sensitivity of Alox12/ mice to
STZ, we employed the 12/15-LOX–specific small-molecule
inhibitor ML351 (32). Alox12/ mice treated with ML351
were protected from STZ-induced glucose intolerance com-
pared with vehicle-treated Alox12/ mice (Fig. 4, F and G).
These results suggest that 12/15-LOX levels in Alox12/
mice augment the sensitivity of these mice to STZ-induced
dysfunction.
Discussion
LOXs form a family of enzymes that catalyze the oxygenation
of cellular polyunsaturated fatty acids to form lipid inflamma-
Figure 3. Alox12 deletion exacerbates reactive oxygen species accumulation in cells. A, ratiometric image of islets fromWT, Alox12/, and Alox15/
mice expressing ROGFP2 ROS sensor at baseline and following overnight treatment with a proinflammatory mixture (P.I.C.; IL1, TNF, and IFN). B, -fold
change of the 405/488 ratio of islets treated with a proinflammatory mixture. n 3 mice/experimental group for all experiments. *, p 0.05.
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torymediators (15, 17). LOXs have been shown to contribute to
the pathogenesis of T1D and T2D.Alox12 encodes for 12-LOX
(also commonly called platelet-type 12-LOX), which catalyzes
the oxygenation of the 12th carbon of its substrates, whereas
Alox15 encodes for 12/15-LOX (also known as leukocyte-type
12-LOX), which oxygenates substrates at either the 12th or
15th carbon (16). 12-LOX–catalyzed oxygenation of arachi-
donic acid leads to formation of the proinflammatory lipid
12-HETE, and 12/15-LOX forms both 12-HETE and 15-HETE
(in a 6:1 ratio) (33). In the setting of diabetes, loss of 12/15-LOX
Table 1
Alox12 deletion decreases circulating eicosanoid levels in mice
5-HETE, 12-HETE, 15-HETE, 12-HEPE, 13-HODE, 17-HDHA and LTB4 levels in serum fromWT, Alox12/, and Alox15/mice. n 3 mice/experimental group for
all experiments. *, p 0.05 versus the WT.
WT Alox15/ Alox12/
Mean (ng/ml) S.E. p value vs. WT Mean (ng/ml) S.E. p value vs. WT Mean (ng/ml) S.E. p value vs. WT
5-HETE 2.88 0.48 - 1.75 0.99 0.270 1.31 0.30 0.264
12-HETE 3433 1143 - 1266 234 0.063 1.01 0.07 0.023*
15-HETE 7.85 2.53 - 3.55 1.60 0.140 2.32 0.81 0.137
12-HEPE 0.89 0.04 - 60.2 6.1 0.001* Not detected *
13-HODE 77.33 24.93 - 35.43 8.88 0.140 29.97 5.24 0.140
17-HDHA 515.0 237.6 - 118.2 25.79 0.090 1.46 0.06 0.080
LTB4 9.78 6.50 - 4.032 2.00 0.165 2.36 2.73 0.145
Figure 4.Alox12deletion increases STZ-inducedoxidativedamage through reciprocal up-regulationofAlox15.A,Alox12gene expression in islets from
WT, Alox12/, and Alox15/ mice. B, Alox15 gene expression in islets from WT, Alox12/, and Alox15/ mice. C, Alox15 gene expression in Min6 cells
following overnight incubation with vehicle or 12-HETE. D, Gpx1 gene expression in Min6 cells following overnight incubation with vehicle or 12-HETE. E,
catalase gene expression in Min6 cells following overnight incubation with vehicle or 12-HETE. F, analysis of glucose tolerance (GTT) in vehicle- or ML351-
treated Alox12/mice 4 days following the STZ regime.G, area under the curve (AUC) analysis of GTTs. n 3mice/experimental group for all experiments. *,
p 0.05.
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has been shown to be protective in both STZ and nonobese
diabetic mouse models of T1D, effects that have been ascribed
to reductions in the levels of 12-HETE (18–20, 33). The proin-
flammatory actions of 12-HETEmay be due to its properties as
a lipid peroxide and via its interactions with its receptor Gpr31
(34, 35). Although 12-HETE is also produced by 12-LOX, a role
of the Alox12 gene in  cell oxidative stress during diabetes
pathogenesis has not been interrogated. In this study, we inter-
rogated the roles of 12/15-LOX and 12-LOX in the develop-
ment of oxidative stress in pancreatic islets by studying their
respective gene knockouts (Alox15 and Alox12) in the context
of T1D models in vivo and in vitro. Although our data confirm
a pro-diabetogenic role of Alox15, we found a protective effect
for Alox12. Our data demonstrate that loss of Alox12 leads to
compensatory hyperactivity of 12/15-LOX encoded by Alox15
(Fig. 5).
We observed that knockout of either Alox12 or Alox15 did
not appear to affect cellmass or glucose homeostasis, findings
that are in concordancewith prior studies that showed no gross
phenotype in unchallenged animals (18, 22). However, a strik-
ing and discordant phenotype between the two knockouts was
observed when islets of these animals were subjected to proin-
flammatory stress using the multiple low-dose STZ protocol.
STZ is selectively taken up by  cells through the Glut2 trans-
porter and leads toDNA alkylation and eventual cell death (36).
Low doses of STZ trigger low-frequency  cell killing, which is
exacerbated by macrophage influx, proinflammatory cytokine
release, and oxidative stress (37). Under these conditions, prior
studies have shown that Alox15/mice are protected from 
cell destruction and hyperglycemia (18). Our results with
Alox15/ mice confirm these prior studies but add the vital
observation that protection from  cell dysfunction may be
caused by reductions in oxidative stress, as judged by reduced
immunostaining for 4-HNE accompanied by enhanced immu-
nostaining for the antioxidant enzymes GPX1 and CAT. In
contrast, we show that Alox12/ mice exhibit exacerbated
hyperglycemia compared with WT controls, with enhanced
immunostaining for 4-HNE in  cells accompanied by reduced
immunostaining for GPX1 and CAT. Our studies provide the
first documented evidence that the enzymes encoded byAlox15
andAlox12 display apparently opposing roles in cell oxidative
stress, notwithstanding that both enzymes produce identical
major products (12-HETE).
At least two possibilities might be invoked to account for the
disparate phenotypes of Alox15/mice and Alox12/mice.
First, it is possible that the products each enzyme produces
and/or their relative ratios can affect the net production of
ROS. In this regard, although arachidonic acid and its metabo-
lites are important in cytokine induced  cell dysfunction (38),
it is not the only substrate for these enzymes, and the preferen-
tial utilization of other key substrates, such as dihomo--lino-
lenic acid or eicosapentaenoic acid (EPA), form products that
may be protective (13, 39). Indeed, we observed an increase in
circulating levels of the EPA-derived metabolite 12-HEPE in
Alox15/ mice that was undetected in the Alox12/ mice.
This finding raises the possibility that loss of Alox15 leads to
preferential use of EPA over arachidonic acid as a product. This
switch to EPAmetabolism has been shown to be protective of
cell function (40). Second, it is possible that the catalytic simi-
larities between the two enzymes might allow one enzyme to
compensate to produce the products of the other. We show
here that. although no up-regulation ofAlox12was observed in
Alox15/mice, there was a nearly 30-fold increase in Alox15
levels inAlox12/mice. The near-reversal of the diabetogenic
phenotype of Alox12/ mice through concurrent pharmaco-
logic inhibition of 12/15-LOX (with ML351) supports the
notion that 12/15-LOX activity contributes to the phenotype of
these animals. We recognize, however, that we cannot rule out
a contribution resulting from the loss of potentially protective
lipid products emanating from 12-LOX activity in Alox12/
mice. Based on the lipidomics analysis, we observed a decrease
in 12-HETE in the Alox12/ mice. This suggests that the
observed detrimental effects observed because of loss of
Alox12/ is not caused by an increase in 12-HETE levels.
Additionally, we show that 12-HETE inhibits the expression of
Alox15 in Min6 cells. Taken together, the observed decrease in
12-HETE in Alox12/ mice could then lead to the observed
up-regulation of Alox15.
In conclusion, our data suggest that Alox15 and Alox12 play
disparate roles in the pathogenesis of  cell oxidative stress and
dysfunction. The observation that Alox15 levels are elevated in
Alox12/ islets also highlights a deficiency in our understand-
ing of the regulation of the genes encoding LOX enzymes. As
inhibitors of LOX enzymes begin to gain traction for disease
modification (32, 41), it will be especially relevant to under-
stand how inhibition of specific enzymes might influence the
expression and activities of other related LOXs. Future studies
unraveling the effect of complete loss versus inhibition of a
lipoxygenase enzyme and possible compensatory effects are
thus warranted.
Figure 5. Proposed model of Alox12 versus Alox15. Deletion of 12/15-
LOX(Alox15) leads to a decrease in 12-HETE levels, an increase in 12-HEPE,
augmentation of the antioxidant response in  cells during oxidative
stress, and increased survival. Deletion of 12-LOX(Alox12), on the other
hand, causes a compensatory increase in 12/15-LOX(Alox15) expression,
loss of 12-HEPE production, inhibition of the antioxidant response, and 
cell dysfunction.
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Materials andmethods
Cells, animals, and procedures
All experiments involving mice were performed with
approval from the IndianaUniversity Institutional Animal Care
and Use Committee. B6.129S2-Alox12tm1Fun/J (Alox12/)
and B6.129S2-Alox15tm1Fun/J (Alox15/) mice were pur-
chased from The Jackson Laboratory and maintained in the
Indiana University School of Medicine animal facilities. WT
mice were littermates from both Alox15 and Alox12 litters. All
mice were maintained under pathogen-free conditions. Male
mice were injected intraperitoneally daily for 5 consecutive
days with saline or streptozotocin at 55mg/kg/day at 8 weeks of
age. A cohort ofmice received the 12/15-LOX inhibitorML351
at 10 mg/kg body weight for 5 days prior, during, and 5 days
post-STZ treatment (32). Glucose measurements and intra-
peritoneal GTTs at 2 g/kg body weight of glucose were per-
formed as described previously (21). At the end of the respec-
tive studies, mice were euthanized, serum was collected, and
pancreata were harvested and fixed for analysis. Alternatively,
mouse islets from both male and female mice were isolated
from collagenase-perfused pancreata and cultured in RPMI
medium as described previously (42, 43). Islets were hand-
picked and allowed to recover overnight in complete medium
before experimentation. The mouse insulinoma cell line Min6
was maintained in high-glucose DMEM with 15% FBS and 1%
penicillin/streptomycin supplemented with 10 mMHEPES and
sodium pyruvate and treated with 100 nM 12-HETE for 24 h,
followed by RNA isolation using the RNeasyMini Kit (Qiagen).
Immunohistochemistry, immunofluorescence, and cell mass
Pancreatawere fixed in 4%paraformaldehyde, sectioned, and
immunostained for insulin as described previously (44). Pan-
creatawere stained by immunofluorescence using the following
primary antibodies: anti-4-HNE antibody (Ab464545, Abcam,
1:100), anti-GPX1 (Santa Cruz), anti-CAT (Santa Cruz), and
anti-insulin antibody (A0564, Dako, 1:500). Alexa Fluor 568
donkey anti-rabbit antibody and Alexa Fluor 488 donkey anti-
guinea pig antibody were used as secondary antibodies (Invit-
rogen). Images were acquired using a Zeiss LSM 700 or LSM
800 confocalmicroscope. 4-HNE immunostainings were quan-
tified bymeasuring pixel density per insulin-positive cell.Cell
mass was calculated as described previously using at least three
pancreas sections 70 m apart from five pancreata per group
(45).
Measurement of cell redox state
Mouse islets were isolated as described above. After over-
night recovery, islets were briefly washed with PBS and dis-
tended by incubation with Accutase (STEMCELL Technol-
ogies) for 1 min at 37 °C. Accutase was then inactivated, and
islets were resuspended in complete islet medium containing
serum. Islets were then transduced with the roGFP2 adeno-
virus for 6 h in complete islet medium. Following transduc-
tion, islets were then transferred to virus-free islet medium
containing a vehicle or proinflammatory cytokine mixture (5
ng/ml IL-1, 10 ng/ml TNF, and 100 ng/ml IFN-) for 16 h.
Islets were then imaged on a Zeiss LSM 700 confocal micro-
scope. The biosensor was sequentially excited with 405- and
488-nm excitation, and GFP fluorescence was collected and
ratioed.
Eicosanoid analysis
Mouse serum collected from WT, Alox12/, and
Alox15/ mice was analyzed by the Washington University
Metabolomics Core for profiling of eicosanoids (5-HETE,
12-HETE, 8-HETE, 15-HETE, 12-HEPE, 13-HODE, 17-HDHA,
and LTB4). Eicosanoids were extracted from 50 l of serum
with 200 l of methanol containing 2 ng each of deuterated
5-HETE-d8, 13-HODE-d4, and LTB4-d4 as the internal stan-
dards. The supernatant was reconstituted with 250 l of water
for MS analyses. Four-point to seven-point calibration stan-
dards of all eicosanoids containing the deuterated internal stan-
dards were prepared for absolute quantification. The sample
analysis was performed with a Shimadzu 20AD HPLC system
and a SIL-20AC autosampler coupled to a tandem mass spec-
trometer (API-6500, Applied Biosystems) operated in multi-
ple reaction monitoring mode. The negative ion ESI mode was
used for detection of these eicosanoids. The plasma extracts
were injected in duplicate for data averaging. Data processing
was conducted with Analyst 1.6.3 (Applied Biosystems).
Real-time RT-PCR
Reverse-transcribed islet and Min6 RNA was analyzed by
real-time PCR using SYBR Green or TaqMan technology.
Primers included Gpx1, Cat, Alox15, and Alox12 (Qiagen). All
samples were corrected for input RNA by normalizing to the
Actb message. All data represent the average of independent
determinations from at least three separate mice.
Statistical analysis
All experiments were completed in at least biological tripli-
cates. All data are presented as the mean S.E. One-way anal-
ysis of variance (with Holm–Sidak’s post test) was used for
comparisons involving more than two conditions, two-way
analysis of variance was used for comparisons with multiple
time points, and two-tailed Student’s t test was used for
comparisons involving two conditions. Prism 8 software
(GraphPad) was used for all statistical analyses. Statistical sig-
nificance was assumed at p 0.05.
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